Lilly-Humana data pact to focus on outcomes

William Fleming
William Fleming

Another drug maker is tapping Humana's claims database for therapeutic study. This time, it's Eli Lilly that wants to access de-identified medical, pharmacy and lab claims data from the payer to gauge the impact of interventions on outcomes and adherence programs, among other areas, according to a joint press release.

Under the terms of the multi-year agreement, the companies will conduct studies related to various disease states, starting with diabetes—a major source of revenue for the drug maker and of costs for the payer.

“Pairing Humana's clinical expertise and rich, de-identified patient data with Lilly's history and experience across many disease states allows us to maximize the potential benefits for patient care and savings,” said William Fleming, president of Humana Pharmacy Solutions.

Comprehensive Health Insights (CHI), a Humana subsidiary which specializes in crunching data assets for health economics and outcomes research (HEOR), will conduct the studies. Methodologies will also include disease management and pharmacoeconomics.

The Lilly deal follows Pfizer's 2011 pact with Humana, which involved real-world data and comparative-effectiveness research.

Initially, the retrospective analysis with Lilly will investigate patient characteristics associated with increased healthcare costs in people with type 2 diabetes.

“Working together, we hope to provide patients with insights and guidance that will help them tailor their care to best match their individual needs,” said Dara Schuster, MD, medical fellow, Lilly Diabetes.

You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.